Press Releases and Media Coverage
May 27, 2026
Roy Maute on Macrophage Checkpoint Inhibition: Pheast’s Vision for Advancing PHST001 in Solid Tumors
April 23, 2026
Drug Discovery World: The next generation of cancer therapies revealed at AACR 2026
April 3, 2026
The Clinical Trial Vanguard: Pheast Therapeutics Advances New Cancer Drug to Phase 1b Trial
March 16, 2026
Roy Maute on The Biotech Startups Podcast (4 Part Series)
November 3, 2025
Drug Target Review: CD24 Emerges as the Next Macrophage Checkpoint
September 25, 2025
BioHub Podcast – Episode 74: Roy Maute, CEO, Pheast Therapeutics
June 9, 2025
OncoLife: Targeting the “Don’t Eat Me Signal,” The Future of Macrophage Checkpoint Inhibitors in Oncology
December 2, 2024
The Bio Report Podcast: Getting Tumors to Say “Eat Me”
November 8, 2024
The Cancer Letter: Preclinical Data Show Anti-CD24 Macrophage Checkpoint Inhibitor Promotes Phagocytosis and Shrinks Tumors
November 6, 2024
GEN: Parallel Platform Approach Slashes Process Development Time
September 3, 2024
Drug Discovery Online: Does Targeting Macrophages Hold The Key For Treating Cancer?
July 31, 2024
Cancer Research: Attacking Cancer Through Activating “Big Eaters” of the Immune System
June 26, 2024
PharmaShots: Macrophage Checkpoint Therapy with Roy Maute from Pheast Therapeutics
January 5, 2024
Drug Target Review: The Potential of CD24 in Cancer Immunotherapy
November 15, 2023
Pheast Featured as One of Nature Biotechnology’s Top Academic Spinouts for 2023